Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device David Dobarro, MD, Marian Urban, MD, Karen Booth, MB, Neil Wrightson, BS, Javier Castrodeza, MD, Jerome Jungschleger, MD, Nicola Robinson-Smith, BA, Andrew Woods, BA, Gareth Parry, FRCP, Stephan Schueler, MD, Guy A. MacGowan, MD, FACC The Journal of Heart and Lung Transplantation Volume 36, Issue 1, Pages 42-49 (January 2017) DOI: 10.1016/j.healun.2016.08.006 Copyright © 2016 International Society for Heart and Lung Transplantation Terms and Conditions
Figure 1 Kaplan-Meier survival curves for aortic valve opening (AVO) in the (A) entire cohort and (B) in the 30-days-out cohort. LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation 2017 36, 42-49DOI: (10.1016/j.healun.2016.08.006) Copyright © 2016 International Society for Heart and Lung Transplantation Terms and Conditions
Figure 2 Kaplan-Meier survival curves. (A) Aortic valve opening (AVO) and combined event-free survival. (B) AVO and pump thromobisis (PT)-free survival. LVAD, left ventricular assist device. The Journal of Heart and Lung Transplantation 2017 36, 42-49DOI: (10.1016/j.healun.2016.08.006) Copyright © 2016 International Society for Heart and Lung Transplantation Terms and Conditions